Skip to content

Transcranial Magnetic Stimulation for Methamphetamine Use Disorder in PLWH

TMS (Transcranial Magnetic Stimulation) for Methamphetamine Use Disorder in People Living With HIV

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06830980
Enrollment
30
Registered
2025-02-17
Start date
2025-03-11
Completion date
2026-12-31
Last updated
2025-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Methamphetamine Use Disorders, HIV

Brief summary

The purpose of this study is to learn more about how accelerated theta burst stimulation affects methamphetamine craving and brain activity. Theta burst stimulation is a unique transcranial magnetic stimulation (TMS) paradigm that is efficient and potent.

Detailed description

The investigators will compare how two theta burst paradigms, intermittent theta burst stimulation (iTBS) and continuous theta burst stimulation (cTBS), compare with sham TMS in changing methamphetamine craving and brain activity. iTBS, cTBS, and sham TMS will be delivered in an accelerated fashion (two sessions daily, separated by 50 minutes). iTBS will be delivered to the left dorsolateral prefrontal cortex (left dorsolateral prefrontal cortex), and cTBS will be delivered to the frontal pole. A brain MRI scan will be done before and after the iTBS/cTBS/sham TMS sessions. The study involves four visits. Each visit will last three hours. Hence, participants will spend a total of 12 hours in the study.

Interventions

DEVICEintermittent theta burst stimulation (iTBS)

iTBS is an excitatory TMS paradigm that delivers 1800 pulses to the left dlPFC. Participants will receive 2 iTBS sessions separated by 50 minutes.

cTBS is an inhibitory TMS paradigm that delivers 1800 pulses to the frontal pole. Participants will receive 2 iTBS sessions separated by 50 minutes.

DEVICESham TMS

Sham TMS delivered with the MagVenture B65 A/P coil

Sponsors

National Center for Advancing Translational Sciences (NCATS)
CollaboratorNIH
Gopalkumar Rakesh
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Intervention model description

Within participant design with a randomized sequence of interventions.

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Adults in the age group 18-65 years * Able to read and understand English * Able to provide informed consent * Diagnosed with HIV * History of current or previous Methamphetamine Use Disorder * Endorse craving for methamphetamine * Demonstrate an attentional bias for methamphetamine

Exclusion criteria

* Traumatic brain injury * h/o seizure disorder * h/o or current diagnosis of schizophrenia * intracranial metal shrapnel * previous adverse effects with TMS * sub-threshold consistency while performing behavioral tasks * lack of attentional bias to methamphetamine cues * a positive pregnancy test for female participants * abnormal brain MRI

Design outcomes

Primary

MeasureTime frameDescription
Cue-induced methamphetamine cravingBaseline and before and after each TMS session up to 4 daysMeasured on the visual analog scale (VAS) Scored 0 to 100 with 0=no craving and 100=the most craving.

Countries

United States

Contacts

Primary ContactPatricia Garth, CRC
psych_research@uky.edu, annette.garth@uky.edu859-382-7611

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026